June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.Unlock Stocks

WHO issues new clinical advice on treating COVID-19 patients

Published 2021-01-26, 09:20 a/m
© Reuters. FILE PHOTO: A logo is pictured outside a building of the WHO in Geneva

GENEVA (Reuters) - The World Health Organization (WHO) issued fresh clinical advice on Tuesday for treating COVID-19 patients, including those displaying persistent symptoms after recovery, and also said it advised using low-dose anti-coagulants to prevent blood clots.

"The other things in the guidance that are new are that COVID-19 patients at home should have the use of pulse oximetry, that's measuring the oxygen levels, so you can identify whether somewhat at home is deteriorating and would be better off having hospital care," WHO spokeswoman Margaret Harris told a U.N. briefing in Geneva.

The WHO advised clinicians to put patients into the awake prone position, on their front, shown to improve the oxygen flow, she said.

"Also we recommend, we suggest the use, of low-dose anti-coagulents to prevent blood clots forming in blood vessels. We suggest the use of lower doses rather than higher doses because higher doses may lead to other problems," Harris said.

She added that a WHO-led team of independent experts, currently in the central Chinese city of Wuhan where the first human cases were detected in December 2019, is due to leave quarantine in the next two days to pursue its work with Chinese researchers on the virus origins.

She declined to commment on reports of delays in roll-out of vaccines in the European Union. She said she had no specific data and the WHO's priority was for health workers in all countries to be vaccinated in the first 100 days of the year.

© Reuters. FILE PHOTO: A logo is pictured outside a building of the WHO in Geneva

AstraZeneca , which developed its shot with Oxford University, told the EU on Friday it could not meet agreed supply targets up to the end of March.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.